Dave Matthews
CBO, Demuris


Demuris is focused on the discovery of new antibiotics that will combat the threat from emerging diseases and the rise of antibiotic resistance. A portfolio of innovative assays is being used to screen for inhibitors that act differently from existing antibiotics. Demuris also provides the opportunity to discover and develop small molecule inhibitors against a range of interesting drug targets, together with the medicinal chemistry expertise needed to add value by making the initial inhibitors more drug-like. The overall output of the Demuris discovery engine will cover a strong intellectual property portfolio for out-licensing to pharmaceutical and biotechnology companies.


Matchmaking Information

Processing. Please wait.